These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22377341)

  • 1. A harm reduction paradox: comparing China's policies on needle and syringe exchange and methadone maintenance.
    Smith K; Bartlett N; Wang N
    Int J Drug Policy; 2012 Jul; 23(4):327-32. PubMed ID: 22377341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid scale up of harm reduction in China.
    Sullivan SG; Wu Z
    Int J Drug Policy; 2007 Mar; 18(2):118-28. PubMed ID: 17689354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human resource development and capacity-building during China's rapid scale-up of methadone maintenance treatment services.
    Li J; Wang C; McGoogan JM; Rou K; Bulterys M; Wu Z
    Bull World Health Organ; 2013 Feb; 91(2):130-5. PubMed ID: 23554525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011.
    Marotta PL; McCullagh CA
    Int J Drug Policy; 2016 Jun; 32():3-10. PubMed ID: 27212656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Needle and syringe exchange programmes and prevalence of HIV infection among intravenous drug users in China.
    Luo W; Wu Z; Poundstone K; McGoogan JM; Dong W; Pang L; Rou K; Wang C; Cao X
    Addiction; 2015 Jan; 110 Suppl 1():61-7. PubMed ID: 25533865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage of harm reduction services and HIV infection: a multilevel analysis of five Chinese cities.
    Wu Q; Kamphuis C; Duo L; Luo J; Chen Y; Richardus JH
    Harm Reduct J; 2017 Feb; 14(1):10. PubMed ID: 28193236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advocacy for harm reduction in China: a new era dawns.
    Reid G; Aitken C
    Int J Drug Policy; 2009 Jul; 20(4):365-70. PubMed ID: 19097773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harm reduction and "clean" community: can Viet Nam have both?
    Khuat TH; Nguyen VA; Jardine M; Moore T; Bui TH; Crofts N
    Harm Reduct J; 2012 Jul; 9():25. PubMed ID: 22769430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?
    Bonny-Noach H
    Isr J Health Policy Res; 2019 Oct; 8(1):75. PubMed ID: 31619286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
    Hammett TM; Wu Z; Duc TT; Stephens D; Sullivan S; Liu W; Chen Y; Ngu D; Des Jarlais DC
    Addiction; 2008 Jan; 103(1):137-45. PubMed ID: 18028519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The furthest left behind: the urgent need to scale up harm reduction in prisons.
    Sander G; Murphy F
    Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studying up harm reduction policy: the office as an assemblage.
    Chen JS
    Int J Drug Policy; 2011 Nov; 22(6):471-7. PubMed ID: 22000601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combination approach on harm reduction programs: the Taiwan experience.
    Lin T; Chen CH; Chou P
    Harm Reduct J; 2016 Jul; 13(1):23. PubMed ID: 27377896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy implementation of methadone maintenance treatment and HIV infection: evidence from Hubei province, China.
    Dai J; Zhao L; Liang Y
    Subst Abuse Treat Prev Policy; 2013 Nov; 8():38. PubMed ID: 24188659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The trajectory of methadone maintenance treatment in Nepal.
    Ambekar A; Rao R; Pun A; Kumar S; Kishore K
    Int J Drug Policy; 2013 Nov; 24(6):e57-60. PubMed ID: 23845916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug use and HIV/AIDS in China.
    Liu Z; Lian Z; Zhao C
    Drug Alcohol Rev; 2006 Mar; 25(2):173-5. PubMed ID: 16627308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of China's response to HIV/AIDS.
    Wu Z; Sullivan SG; Wang Y; Rotheram-Borus MJ; Detels R
    Lancet; 2007 Feb; 369(9562):679-90. PubMed ID: 17321313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of the current status of needle and syringe exchange programmes for injecting drug users in China].
    Tian ML; Xu J; Luo W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Dec; 43(12):1907-1911. PubMed ID: 36572462
    [No Abstract]   [Full Text] [Related]  

  • 19. Methadone maintenance therapy outcomes in Iran.
    Noori R; Narenjiha H; Aghabakhshi H; Habibi G; Khoshkrood Mansoori B
    Subst Use Misuse; 2012 Jun; 47(7):767-73. PubMed ID: 22416897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.